Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | THPO | P40225 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 3/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.37 |
| ▸ | CA9 | Q16790 | 2/20 | 0.37 |
| ▸ | CA3 | P07451 | 1/20 | 0.37 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | CA6 | P23280 | 1/20 | 0.37 |
| ▸ | CA5A | P35218 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4659641 | 1.00 | SMN1; SMN2 (0.43) | SMN1; SMN2KDM4EMAPTTHRBALOX15 | |
| SCHEMBL4660645 | 1.00 | SMN1; SMN2 (0.43) | SMN1; SMN2KDM4EMAPTTHRBALOX15 | |
| SCHEMBL3898983 | 0.84 | L3MBTL1 (0.50) | SMN1; SMN2KDM4EMAPTTHRBALOX15 | |
| SCHEMBL12064041 | 0.84 | SMN1; SMN2 (0.45) | SMN1; SMN2KDM4EMAPTTHRBALOX15 | |
| SCHEMBL12064029 | 0.84 | SMN1; SMN2 (0.45) | SMN1; SMN2KDM4EMAPTTHRBALOX15 | |
| SCHEMBL12064309 | 0.84 | SMN1; SMN2 (0.45) | SMN1; SMN2KDM4EMAPTTHRBALOX15 | |
| SCHEMBL13198959 | 0.84 | CA1 (0.42) | SMN1; SMN2CA1CA2BIRC2CA12 | |
| SCHEMBL3241409 | 0.83 | TAS1R3 (0.46) | SMN1; SMN2KDM4EMAPTTHRBALOX15 | |
| SCHEMBL711890 | 0.83 | TAS1R3 (0.46) | SMN1; SMN2KDM4EMAPTTHRBALOX15 | |
| SCHEMBL13993116 | 0.82 | CA1 (0.41) | SMN1; SMN2CA1CA2BIRC2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250083136-A1 | METHODS AND SYSTEMS FOR MODIFYING SELECTIVITY IN CATALYTIC REACTIONS | U.S. DEPARTMENT OF ENERGY | 2025-03-13 | — | — | US | disclosed |
| WO-2018071741-A1 | SULFOXYALKYL ORGANONITRO AND RELATED COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR USE IN MEDICINE | EPICENTRIX, INC. (US) | 2018-04-19 | — | — | WO | disclosed |
| US-9468625-B2 | Organonitro thioether compounds and medical uses thereof | EPICENTRX, INC. (US) | 2016-10-18 | — | — | US | disclosed |
| US-20160081981-A1 | ORGANONITRO THIOETHER COMPOUNDS AND MEDICAL USES THEREOF | RADIORX, INC. | 2016-03-24 | — | — | US | disclosed |
| US-20150315227-A1 | PHOSPHOROUS PROTECTING GROUPS AND METHODS OF PREPARATION AND USE THEREOF | UNIVERSITY OF COLORADO BOULDER | 2015-11-05 | — | — | US | disclosed |
| WO-2015168461-A2 | PHOSPHOROUS PROTECTING GROUPS AND METHODS OF PREPARATION AND USE THEREOF | AGILENT TECHNOLOGIES, INC. (US) | 2015-11-05 | — | — | WO | disclosed |
| US-9139519-B2 | Organonitro thioether compounds and medical uses thereof | EPICENTRX, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-20140349988-A1 | ORGANONITRO THIOETHER COMPOUNDS AND MEDICAL USES THEREOF | RADIORX, INC. (US) | 2014-11-27 | — | — | US | disclosed |
| US-8114858-B2 | Derivatives of 4- or 5-aminosalicylic acid | ANTIBE THERAPEUTICS INC. (CA) | 2012-02-14 | — | — | US | disclosed |
| US-8114857-B2 | Derivatives of 4- or 5-aminosalicylic acid | ANTIBE THERAPEUTICS INC. (CA) | 2012-02-14 | — | — | US | disclosed |
| US-20090209511-A1 | Benzofuran Derivatives | KAWAGUCHI TAKAYUKI | 2009-08-20 | — | — | US | disclosed |
| US-7531537-B2 | Benzofuran derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-05-12 | — | — | US | disclosed |
| US-20090082372-A1 | Arylmethylene Substituted N-Acyl-Beta-Amino Alcohols | BAYER SCHERING PHARMA AG (DE) | 2009-03-26 | — | — | US | disclosed |
| EP-1279660-B1 | Process for producing an optically active amide from an alpha, beta-unsaturated amide derivative in the presence of an optically active transition metal complex containing a phosphine-phosphorane compound and rhodium | TAKASAGO PERFUMERY CO LTD (JP) | 2008-12-17 | — | — | EP | disclosed |
| US-20070292476-A1 | Delivery of ophthalmologic agents to the exterior or interior of the eye | MEDIVAS, LLC (US) | 2007-12-20 | — | — | US | disclosed |
| CN-1309728-C | Chiral organic, inorganic polymer assembled catalyst, synthesis method and use | SHANGHAI INST ORGANIC CHEM (CN) | 2007-04-11 | — | — | CN | disclosed |
| CN-1597114-A | Chiral organic, inorganic polymer assembled catalyst, synthesis method and use | SHANGHAI INST ORGANIC CHEM (CN) | 2005-03-23 | — | — | CN | disclosed |
| US-6855847-B2 | Process for producing optically active amide from α β- unsaturated amide derivative in the presence of transition metal complex containing phosphine-phosphorane compound and transition metal | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2005-02-15 | — | — | US | disclosed |
| US-20030120067-A1 | Process for producing optically active amide from alpha beta- unsaturated amide derivative in the presence of transition metal complex containing phosphine-phosphorane compound and transition metal | TAKASAGO INTERNATIONAL CORPORATION | 2003-06-26 | — | — | US | disclosed |
| EP-1279660-A1 | Process for producing an optically active amide from an alpha, beta-unsaturated amide derivative in the presence of a transition metal complex containing a phosphine-phosphorane compound and a transition metal | Takasago International Corporation (JP) | 2003-01-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250083136-A1 | METHODS AND SYSTEMS FOR MODIFYING SELECTIVITY IN CATALYTIC REACTIONS | HMBS, UNG, MPG | SMN1; SMN2 3203/4885KDM4E 1712/4885MAPT 4305/4885 |
| US-20070292476-A1 | Delivery of ophthalmologic agents to the exterior or interior of the eye | UACA, USP36, FAU | SMN1; SMN2 4376/4885KDM4E 1738/4885MAPT 688/4885 |
| US-20030120067-A1 | Process for producing optically active amide from alpha beta- unsaturated amide derivative in the presence of transition metal complex containing phosphine-phosphorane compound and transition metal | PHOSPHO1, NAAA, DEGS1 | SMN1; SMN2 2984/4885KDM4E 4438/4885MAPT 3373/4885 |
| US-20150315227-A1 | PHOSPHOROUS PROTECTING GROUPS AND METHODS OF PREPARATION AND USE THEREOF | POLN, POLRMT, NUDT21 | SMN1; SMN2 362/4885KDM4E 3963/4885MAPT 4148/4885 |
| US-20090209511-A1 | Benzofuran Derivatives | F12, F2, F3 | SMN1; SMN2 3067/4885KDM4E 1464/4885MAPT 4681/4885 |
| US-20140349988-A1 | ORGANONITRO THIOETHER COMPOUNDS AND MEDICAL USES THEREOF | SLC22A8, SLCO2A1, SLCO2B1 | SMN1; SMN2 1765/4885KDM4E 747/4885MAPT 2777/4885 |
| US-20160081981-A1 | ORGANONITRO THIOETHER COMPOUNDS AND MEDICAL USES THEREOF | SLC22A8, XPOT, NPM1 | SMN1; SMN2 2323/4885KDM4E 1061/4885MAPT 2770/4885 |
| US-20090082372-A1 | Arylmethylene Substituted N-Acyl-Beta-Amino Alcohols | FSHR, SHBG, NAT1 | SMN1; SMN2 2238/4885KDM4E 1126/4885MAPT 4680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.